Journal of Oncology Translational Research

ISSN: 2476-2261

Open Access

Current Issue

Volume 5, Issue 1 (2019)

    Review Article Pages: 1 - 5

    Persisting Challenges in Prevention, Management and Prediction of Prognosis in Cervical Cancer

    S. Chhabra

    DOI: 10.4172/2476-2261.1000134

    Introduction: It is possible to prevent mortality due to cervical cancer by appropriate and timely therapy. But it continues to be a major contributor of cancer related deaths globally because of failure in prevention, early detection and timely, appropriate therapy.
    Objectives: Objective was to collect information about persisting challenges in management, prevention, prediction of prognosis of cervical cancer.
    Methodology: A Simple review was done by using Up-to-date, ERMED CONSORTIUM, Cochrane Library, Delnet, MedIND to get information from available studies and reviews related to prevention, management, prediction of prognosis in cervical cancer and personal experiences were added.
    Results: Usually, management of cervical cancer is as per age, parity, stage of cancer, associated disorders. It may be conservative or aggressive multimodality therapy. However after planned therapy outcome is not always as per expectations. Answers need research. Nearly 20% of women with cervical cancer die within the first year of diagnosis. Research continues about factors which affect outcome and recurrence after surgery, radiotherapy, chemoradiotherapy, and differences in efficacy of surgery, chemotherapy, radiotherapy. Despite significant developments in management, results seem to be far from optimal. Over years there has been no demonstrable reduction in the incidence of cervical cancer and deaths due to cervical cancer. More than 50% of women diagnosed with cervical cancer are younger than 50 years, so the quality of life is becoming a challenge. Sometimes extensive surgeries like complete or anterior or posterior exenteration might give satisfaction to treating surgeon but what matters is survival with quality. It is not possible to predict the prognosis and know the best therapy for recurrent disease. In developing countries lack of awareness about prevention, geographical, economic inaccessibility, poor quality services, lack of support from families are barriers to early diagnosis and also safe therapy. A lot of more research seems to be necessary for the best therapy.
    Conclusion: In spite of being almost preventable cancer mortality due to cervical cancer continues to be high. At present, it is mostly not possible to predict prognosis. Appropriate management needs more research and a lot needs to be researched about prognosis too.

    Research Article Pages: 1 - 5

    The Role of 18-FDG PET/CT Metabolic Parameters in Predicting Prognosis in Advanced Intrahepatic Cholangiocarcinoma

    Esat Namal and Refik Bilgin

    DOI: 10.4172/2476-2261.1000135

    Objective: Intrahepatic cholangiocarcinoma is the second most frequently encountered primary tumor of the liver after hepatocellular carcinoma. In patients who do not have surgical or other local treatment options, systemic chemotherapy is the standard treatment. However, prognostic factors are not clear for patients with advanced disease who do not have the ability to undergo a surgical operation. In many tumors, there are studies demonstrating the pretreatment effect of positron emission tomography with fluorodeoxyglucose (FDG-PET) metabolic parameters on the prognosis. However, there are a small number of studies that research the effect of FDG-PET metabolic parameters on the prognosis in advanced intrahepatic cholangiocarcinoma. We aimed to investigate the relationship between FDGPET metabolic parameters and survival in advanced intrahepatic cholangiocarcinoma.
    Methods: The medical records of 50 advanced intrahepatic cholangiocarcinoma patients from Istanbul Bilim University Medical Oncology Clinic between 2012 and 2018 were reviewed retrospectively. The relationship between patient survival, demographic characteristics and FDG-PET metabolic parameters (SUVmax, metabolic tumor volume, and total lesion glycolysis) was analyzed.
    Results: Each unit of increase in metabolic tumor volume increases the risk of death by 1.0057 times, and each unit of increase in total lesion glycolysis increases the risk of death by 1.0034 times. The Cox regression model was found to be significant for metabolic tumor volume and total lesion glycolysis values but not for SUVmax values.
    Conclusion: FDG-PET metabolic parameters, such as metabolic tumor volume and total lesion glycolysis, contribute to the prognosis, and routine measurement of these parameters will be beneficial.

Recommended Conferences

Oncology 2020

Paris, France

Cancer Meet 2020

San Francisco, USA
arrow_upward arrow_upward